What is the current valuation of the Oncolytic Virus Immunotherapy Market as of 2024?

The Oncolytic Virus Immunotherapy Market was valued at 4.399 USD Billion in 2024. Read More

What is the projected market size for the Oncolytic Virus Immunotherapy Market in 2035?

The market is projected to reach 31.57 USD Billion by 2035. Read More

What is the expected CAGR for the Oncolytic Virus Immunotherapy Market during the forecast period 2025 - 2035?

The expected CAGR for the Oncolytic Virus Immunotherapy Market during 2025 - 2035 is 19.62%. Read More

Which cancer types are leading in market valuation within the Oncolytic Virus Immunotherapy sector?

Lung cancer and melanoma are leading, with valuations of 9.12 USD Billion and 5.99 USD Billion, respectively. Read More

What are the key virus types utilized in Oncolytic Virus Immunotherapy?

Key virus types include Adenovirus, valued at 9.25 USD Billion, and Newcastle Disease Virus, valued at 9.57 USD Billion. Read More

How does the route of administration impact the Oncolytic Virus Immunotherapy Market?

Intratumoral administration is projected to reach 10.5 USD Billion, indicating its significant role in the market. Read More

What technologies are being employed in the Oncolytic Virus Immunotherapy Market?

The market features Genetically Modified Viruses, projected to reach 19.25 USD Billion, highlighting their importance. Read More

Who are the key players in the Oncolytic Virus Immunotherapy Market?

Key players include Amgen, Bristol-Myers Squibb, and Merck & Co., among others. Read More

What is the market valuation for colorectal cancer within the Oncolytic Virus Immunotherapy segment?

Colorectal cancer is valued at 4.59 USD Billion, reflecting its position in the market. Read More

How does the Oncolytic Virus Immunotherapy Market compare across different cancer types?

Lung cancer leads with 9.12 USD Billion, while prostate cancer follows closely at 4.63 USD Billion. Read More

Oncolytic Virus Immunotherapy Market

Oncolytic Virus Immunotherapy Market Research Report By Type of Cancer (Melanoma, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer), By Virus Type (Herpes Simplex Virus, Adenovirus, Reovirus, Vaccinia Virus, Newcastle Disease Virus), By Route of Administration (Intratumoral, Intravenous, Intraperitoneal, Subcutaneous), By Technology (Genetically Modified Virus, Wild-type Virus) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

19.62%

2024 Market Size

$ 4.4 Billion

2035 Market Size

$ 31.57 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/32294-HCR | Pages: 100 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type of Cancer (USD Billion) | |
  1. 4.1.1 Melanoma | |
  2. 4.1.2 Lung Cancer | |
  3. 4.1.3 Breast Cancer | |
  4. 4.1.4 Colorectal Cancer | |
  5. 4.1.5 Prostate Cancer |
2. 4.2 Healthcare, BY Virus Type (USD Billion) | |
  1. 4.2.1 Herpes Simplex Virus | |
  2. 4.2.2 Adenovirus | |
  3. 4.2.3 Reovirus | |
  4. 4.2.4 Vaccinia Virus | |
  5. 4.2.5 Newcastle Disease Virus |
3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.3.1 Intratumoral | |
  2. 4.3.2 Intravenous | |
  3. 4.3.3 Intraperitoneal | |
  4. 4.3.4 Subcutaneous |
4. 4.4 Healthcare, BY Technology (USD Billion) | |
  1. 4.4.1 Genetically Modified Virus | |
  2. 4.4.2 Wild-type Virus |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Amgen (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bristol-Myers Squibb (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Merck & Co. (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Roche (CH) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Oncolytics Biotech (CA) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 SillaJen (KR) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Transgene (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Viralytics (AU) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Iovance Biotherapeutics (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE OF CANCER |
7. 6.4 US MARKET ANALYSIS BY VIRUS TYPE |
8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
9. 6.6 US MARKET ANALYSIS BY TECHNOLOGY |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF CANCER |
11. 6.8 CANADA MARKET ANALYSIS BY VIRUS TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
13. 6.10 CANADA MARKET ANALYSIS BY TECHNOLOGY |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF CANCER |
16. 6.13 GERMANY MARKET ANALYSIS BY VIRUS TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
18. 6.15 GERMANY MARKET ANALYSIS BY TECHNOLOGY |
19. 6.16 UK MARKET ANALYSIS BY TYPE OF CANCER |
20. 6.17 UK MARKET ANALYSIS BY VIRUS TYPE |
21. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
22. 6.19 UK MARKET ANALYSIS BY TECHNOLOGY |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF CANCER |
24. 6.21 FRANCE MARKET ANALYSIS BY VIRUS TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
26. 6.23 FRANCE MARKET ANALYSIS BY TECHNOLOGY |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF CANCER |
28. 6.25 RUSSIA MARKET ANALYSIS BY VIRUS TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
30. 6.27 RUSSIA MARKET ANALYSIS BY TECHNOLOGY |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF CANCER |
32. 6.29 ITALY MARKET ANALYSIS BY VIRUS TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
34. 6.31 ITALY MARKET ANALYSIS BY TECHNOLOGY |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF CANCER |
36. 6.33 SPAIN MARKET ANALYSIS BY VIRUS TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
38. 6.35 SPAIN MARKET ANALYSIS BY TECHNOLOGY |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF CANCER |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY VIRUS TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF CANCER |
45. 6.42 CHINA MARKET ANALYSIS BY VIRUS TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
47. 6.44 CHINA MARKET ANALYSIS BY TECHNOLOGY |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF CANCER |
49. 6.46 INDIA MARKET ANALYSIS BY VIRUS TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
51. 6.48 INDIA MARKET ANALYSIS BY TECHNOLOGY |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF CANCER |
53. 6.50 JAPAN MARKET ANALYSIS BY VIRUS TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
55. 6.52 JAPAN MARKET ANALYSIS BY TECHNOLOGY |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF CANCER |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY VIRUS TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF CANCER |
61. 6.58 MALAYSIA MARKET ANALYSIS BY VIRUS TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
63. 6.60 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF CANCER |
65. 6.62 THAILAND MARKET ANALYSIS BY VIRUS TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
67. 6.64 THAILAND MARKET ANALYSIS BY TECHNOLOGY |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF CANCER |
69. 6.66 INDONESIA MARKET ANALYSIS BY VIRUS TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
71. 6.68 INDONESIA MARKET ANALYSIS BY TECHNOLOGY |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF CANCER |
73. 6.70 REST OF APAC MARKET ANALYSIS BY VIRUS TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
75. 6.72 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF CANCER |
78. 6.75 BRAZIL MARKET ANALYSIS BY VIRUS TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
80. 6.77 BRAZIL MARKET ANALYSIS BY TECHNOLOGY |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF CANCER |
82. 6.79 MEXICO MARKET ANALYSIS BY VIRUS TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
84. 6.81 MEXICO MARKET ANALYSIS BY TECHNOLOGY |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF CANCER |
86. 6.83 ARGENTINA MARKET ANALYSIS BY VIRUS TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
88. 6.85 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF CANCER |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY VIRUS TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF CANCER |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY VIRUS TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF CANCER |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY VIRUS TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF CANCER |
103. 6.100 REST OF MEA MARKET ANALYSIS BY VIRUS TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
105. 6.102 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE OF CANCER, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE OF CANCER, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY VIRUS TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY VIRUS TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE OF CANCER, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY VIRUS TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY TECHNOLOGY, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Oncolytic Virus Immunotherapy Market Segmentation

Oncolytic Virus Immunotherapy Market By Type of Cancer (USD Billion, 2025-2035)

Melanoma
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer

Oncolytic Virus Immunotherapy Market By Virus Type (USD Billion, 2025-2035)

Herpes Simplex Virus
Adenovirus
Reovirus
Vaccinia Virus
Newcastle Disease Virus

Oncolytic Virus Immunotherapy Market By Route of Administration (USD Billion, 2025-2035)

Intratumoral
Intravenous
Intraperitoneal
Subcutaneous

Oncolytic Virus Immunotherapy Market By Oncolytic Virus Immunotherapy Market (USD Billion, 2025-2035)

Genetically Modified Virus
Wild-type Virus

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”